These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27001494)

  • 1. Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients.
    de Oliveira Machado E; Lima CH; Ogino LL; Kasuki L; Gadelha MR
    Pituitary; 2016 Aug; 19(4):375-80. PubMed ID: 27001494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly.
    Pontes J; Madeira M; Lima CHA; Ogino LL; de Paula Paranhos Neto F; de Mendonça LMC; Farias MLF; Kasuki L; Gadelha MR
    J Endocrinol Invest; 2020 Feb; 43(2):163-171. PubMed ID: 31392573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
    Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
    Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.
    Schmid C; Krayenbuehl PA; Bernays RL; Zwimpfer C; Maly FE; Wiesli P
    Clin Chem; 2007 Aug; 53(8):1484-8. PubMed ID: 17573420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.
    Mercado M; González B; Sandoval C; Esquenazi Y; Mier F; Vargas G; de los Monteros AL; Sosa E
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3411-5. PubMed ID: 18611972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
    Montefusco L; Filopanti M; Ronchi CL; Olgiati L; La-Porta C; Losa M; Epaminonda P; Coletti F; Beck-Peccoz P; Spada A; Lania AG; Arosio M
    Clin Endocrinol (Oxf); 2010 May; 72(5):661-7. PubMed ID: 20447065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
    Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
    Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
    Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
    J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
    Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
    Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.
    Cinar N; Dagdelen S; Yorgun H; Canpolat U; Kabakçı G; Erbas T
    Pituitary; 2015 Feb; 18(1):116-25. PubMed ID: 24706164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GH receptor isoforms and skeletal fragility in acromegaly.
    Mormando M; Nasto LA; Bianchi A; Mazziotti G; Giampietro A; Pola E; Pontecorvi A; Giustina A; De Marinis L
    Eur J Endocrinol; 2014 Aug; 171(2):237-45. PubMed ID: 24866575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.
    Filopanti M; Olgiati L; Mantovani G; Corbetta S; Arosio M; Gasco V; De Marinis L; Martini C; Bogazzi F; Cannavò S; Colao A; Ferone D; Arnaldi G; Pigliaru F; Peri A; Angeletti G; Jaffrain-Rea ML; Lania AG; Spada A
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E165-72. PubMed ID: 22162472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly.
    Bianchi A; Mazziotti G; Tilaro L; Cimino V; Veltri F; Gaetani E; Pecorini G; Pontecorvi A; Giustina A; De Marinis L
    Pituitary; 2009; 12(3):196-9. PubMed ID: 19089622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor.
    Blum WF; Machinis K; Shavrikova EP; Keller A; Stobbe H; Pfaeffle RW; Amselem S
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4171-4. PubMed ID: 16868057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
    Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
    Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency.
    Andujar-Plata P; Fernandez-Rodriguez E; Quinteiro C; Casanueva FF; Bernabeu I
    Pituitary; 2015 Feb; 18(1):101-7. PubMed ID: 24710993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
    Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
    Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature.
    Toyoshima MT; Castroneves LA; Costalonga EF; Mendonca BB; Arnhold IJ; Jorge AA
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):500-4. PubMed ID: 17555512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly.
    Kamenicky P; Dos Santos C; Espinosa C; Salenave S; Galland F; Le Bouc Y; Maison P; Bougnères P; Chanson P
    Eur J Endocrinol; 2009 Aug; 161(2):231-5. PubMed ID: 19439509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.